Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
570.5 DKK | +0.09% | -3.81% | +22.57% |
Apr. 22 | U.S. Futures, European Stocks Rise | DJ |
Apr. 16 | GRI Bio Receives South Korea Patent for Liver Inflammatory Condition Treatments | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- The company is in a robust financial situation considering its net cash and margin position.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
Weaknesses
- The company benefits from high valuations in earnings multiples.
- The company is not the most generous with respect to shareholders' compensation.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Electrical Components & Equipment
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+22.57% | 4.36B | B | ||
+2.60% | 145B | A | ||
+13.65% | 122B | B+ | ||
+27.93% | 123B | B+ | ||
+11.61% | 62.1B | A- | ||
+7.87% | 41.12B | B | ||
+3.68% | 30.93B | B | ||
-11.92% | 31.34B | B | ||
+58.38% | 29.06B | C | ||
+2.19% | 26.43B | A- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- NKT Stock
- Ratings NKT A/S